Three Pharmaceutical Manufacturing Change Agents Profiled in C&EN

June 25, 2007
Former Chemical Week colleague Rick Mullin, now a senior editor with Chemical and Engineering News, just wrote a nice piece profiling three individuals who are helping to bring drug manufacturing into the 21st century, by taking a more "operations" and "results" oriented approach.  They are:  William Deese, President of Merck's manufacturing division, Novartis' Mark Fishman, President of Novartis' NIBR and Pfizer's Robin Spencer, who is bringing high throughput screening to more of the company's R&D efforts. To read this update, click here. -AMS
Former Chemical Week colleague Rick Mullin, now a senior editor with Chemical and Engineering News, just wrote a nice piece profiling three individuals who are helping to bring drug manufacturing into the 21st century, by taking a more "operations" and "results" oriented approach.  They are:  William Deese, President of Merck's manufacturing division, Novartis' Mark Fishman, President of Novartis' NIBR and Pfizer's Robin Spencer, who is bringing high throughput screening to more of the company's R&D efforts. To read this update, click here. -AMS
About the Author

pharmamanufacturing | pharmamanufacturing